Abstract
Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have